Impact of increased APP gene dose in Down syndrome and the Dp16 mouse model,Alzheimer's & Dementia

当前位置： X-MOL 学术 › Alzheimers Dement. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Impact of increased APP gene dose in Down syndrome and the Dp16 mouse model
Alzheimer's & Dementia ( IF 14.0 ) Pub Date : 2021-11-10 , DOI: 10.1002/alz.12463
Mariko Sawa ₁ , Cassia Overk ₁ , Ann Becker ₁ , Dominique Derse ₁ , Ricardo Albay ₁ , Kim Weldy ₁ , Ahmad Salehi ₂ , Thomas G Beach ₃ , Eric Doran ₄ , Elizabeth Head ₅ , Y Eugene Yu ₆ , William C Mobley ₁

Affiliation

People with Down syndrome (DS) are predisposed to Alzheimer's disease (AD). The amyloid hypothesis informs studies of AD. In AD-DS, but not sporadic AD, increased APP copy number is necessary, defining the APP gene dose hypothesis. Which amyloid precursor protein (APP) products contribute needs to be determined.

中文翻译：

增加 APP 基因剂量对唐氏综合症和 Dp16 小鼠模型的影响

患有唐氏综合症 (DS) 的人易患阿尔茨海默病 (AD)。淀粉样蛋白假说为 AD 研究提供了信息。在 AD-DS 中，但不是散发性 AD，增加 APP 拷贝数是必要的，定义了 APP 基因剂量假说。需要确定哪些淀粉样前体蛋白 (APP) 产品有贡献。

更新日期：2021-11-10

点击分享查看原文

点击收藏

阅读更多本刊最新论文

全部期刊列表>>